Matrix Metalloproteinase Inhibitors in Cancer Therapy

1. Front Matter

   Pages i-xiii

   PDF

2. Biology and Regulation of the Matrix Metalloproteinases

   • Mark D. Sternlicht, Lisa M. Coussens, Thiennu H. Vu, Zena Werb

   Pages 1-37

3. Substrate Specificity of MMPs

   • Hideaki Nagase

   Pages 39-66

4. The Tissue Inhibitors of Metalloproteinases (TIMPs)

   • Dylan R. Edwards

   Pages 67-84

5. Matrix Metalloproteinases in Cancer

   • Barbara Fingleton, Lynn M. Matrisian

   Pages 85-112

6. Hydroxamic Acid Matrix Metalloproteinase Inhibitors

   • Peter D. Brown, Alan H. Davidson, Alan H. Drummond, Andrew Gearing, Mark Whittaker

   Pages 113-142

7. Prinomastat

   • David R. Shalinsky, Bhasker Shetty, Yazdi Pithavala, Steve Bender, Anthony Neri, Stephanie Webber et al.

   Pages 143-173

8. A Potent Nonpeptidic Matrix Metalloproteinase Inhibitor

   • G. Clemens, B. Hibner, R. Humphrey, H. Kluender, S. Wilhelm

   Pages 175-192

9. D1927 and D2163

   • A. D. Baxter, J. B. Bird, R. Bannister, R. Bhogal, D. T. Manallack, R. W. Watson et al.

   Pages 193-221

10. Research on MMP Inhibitors with Unusual Scaffolds

    • Frank Grams, Hans Brandstetter, Richard A. Engh, Dagmar Glitz, Hans-Willi Krell, Valeria Livi et al.

    Pages 223-243

11. Matrix Metalloproteinase Inhibitors

    • Michael R. Niesman

    Pages 245-254

12. Back Matter

    Pages 255-262

    PDF

Cutting-edge investigators review the current status of the entire field, from the biology of MMPs through the current clinical studies. The authors include many leading scientists from pharmaceutical companies who present all the latest concepts and results on the preferred design strategies for MMP inhibitors, their molecular mechanisms, and their substrates. In addition, they fully describe their personal research on specific MMP inhibitors, detailing vanguard design strategies, their in vitro activity, the outcome of animal model studies and, where available, their toxicology, safety, efficacy in human clinical trials.
Comprehensive and state-of-the-art, Matrix Metalloproteinase Inhibitors in Cancer Therapy offers basic and clinical investigators alike a richly informative summary of all the latest research on these powerful new drugs, and their high promise as emerging cancer therapeutics.

• cancer
• cancer therapy
• clinical trial
• oncology
• research
• toxicology

• Corporate V.P., Clinical Affairs, Agouron Pharmaceuticals Inc., San Diego, USA

  Neil J. Clendeninn

• Department of Research Pharmacology, Agouron Pharmaceuticals Inc., San Diego, USA

  Krzysztof Appelt

Policies and ethics